The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: A meta-analysis of the diagnostic accuracy

International Journal of Cancer

Volumn 132, Issue 1, 2013, Pages 101-108

  Arbyn, Marc ^a   Roelens, Jolien ^a   Cuschieri, Kate ^b   Cuzick, Jack ^c   Szarewski, Ann ^c   Ratnam, Sam ^d   Reuschenbach, Miriam ^e   Belinson, Suzanne ^f   Belinson, Jerome L ^f   Monsonego, Joseph ^g  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f Preventive Oncology International Inc   (United States)

^g Institute of the Cervix   (France)

Author keywords

APTIMA; atypical squamous cells of undetermined significance; cervical cancer screening; diagnostic test accuracy; HPV; hybrid capture; low grade squamous intraepithelial lesions; meta analysis; triage

Indexed keywords

RNA; VIRUS DNA; VIRUS RNA;

ADULT; APTIMA HPV ASSAY; ARTICLE; ASSAY; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; EMERGENCY HEALTH SERVICE; FEMALE; HIGH RISK PATIENT; HUMAN; HYBRID CAPTURE 2 TEST; INTERMETHOD COMPARISON; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; META ANALYSIS; PRIORITY JOURNAL; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VALIDATION PROCESS; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; TRIAGE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84868198169     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27636     Document Type: Article

References (50)

1. Jordan J, Arbyn M, Martin-Hirsch P, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, Part 1. Cytopathology 2008; 19: 342-54.
2. Partridge EE, Abu-Rustum NR, Campos SM, et al. Cervical cancer screening: NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2010; 8: 1358-86.
3. Stampler KM, Dunton CJ,. Cervical neoplasia guidelines: United States and Europe compared. J Low Genit Tract Dis 2010; 14: 142-7.
4. Wright TC, Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197: 346-55.
5. Solomon D, Papillo JL, Davey DD,. Statement on HPV DNA test utilization. Am J Clin Pathol 2009; 131: 768-9.
6. Sorbye SW, Fismen S, Gutteberg T, et al. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. PLoS One 2010; 5: e12724 (1)-e12724 (6).
7. TOMBOLA Group. Cytological surveillance compared with immediate referral for colposcopy in management of women with low grade cervical abnormalities: multicentre randomised controlled trial. BMJ 2009; 339: b2546-b2557.
8. Kelly RS, Patnick J, Kitchener HC, et al. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer 2011; 105: 983-8.
9. Sorbye SW, Arbyn M, Gutteberg T, et al. Triage of women with low-grade cervical lesionsa-HPV mRNA testing versus repeat cytology. PLoS One 2011; 6: e24083-1-e24083-6.
10. Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998; 92: 727-35.
11. Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999; 91: 252-8.
12. Lorincz AT,. Hybrid capture. Clin Chem 1998; 44: 1363.
13. Arbyn M, Buntinx F, Van Ranst M, et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004; 96: 280-93.
14. Arbyn M, Sasieni P, Meijer CJ, et al. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24 (Suppl. 3): S78-S89.
15. Cuzick J, Arbyn M, Ronco G, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26 (Suppl. 10): K29-K41.
16. ASCUS-LSIL Triage Study Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188: 1383-92.
17. ASCUS-LSIL Triage Study Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003; 188: 1393-400.
18. Arbyn M, Paraskevaidis E, Martin-Hirsch P, et al. Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN. An update of pooled evidence. Gynecol Oncol 2005; 99 (Suppl. 3): 7-11.
19. Arbyn M, Martin-Hirsch P, Buntinx F, et al. Triage of women with equivocal or low-grade cervical cytology results. A meta-analysis of the HPV test positivity rate. J Cell Mol Med 2009; 13: 648-59.
20. Ronco G, Cuzick J, Segnan N, et al. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer 2007; 43: 476-80.
21. Castle PE, Fetterman B, Thomas CJ, et al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol 2010; 116: 76-84.
22. Dockter J, Schroder A, Eaton B, et al. Analytical characterization of the APTIMA HPV assay. J Clin Virol 2009; 45 (Suppl. 1): S39-S47.
23. Lundberg GD, National Cancer Institute. The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses. JAMA 1989; 262: 931-4.
24. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-19.
25. Evans DMD, Hudson EA, Brown CL, et al. Terminology in gynaecological cytopathology: report of the working party of the BSCC. J Clin Pathol 1986; 39: 933-44.
26. Dockter J, Schroder A, Hill C, et al. Clinical performance of the APTIMA HPV assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 2009; 45: S55-S61.
27. Whiting P, Rutjes AWS, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 1-13.
28. Dersimonian R, Laird NM,. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 177-88.
29. Harbord RM, Deeks JJ, Egger M, et al. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007; 8: 239-51.
30. Harbord RM, Whiting P,. Metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata J 2009; 9: 211-29.
31. Takwoingi Y, Diagnostic Test Accuracy Working Group. METADAS: a SAS macro for meta-analysis of diagnostic accuracy studies. Available from: http://srdta.cochrane.org/sites/srdta.cochrane.org/files/uploads/ METADAS%20Quick%20Reference%20WorkedExample%20v1.3.pdf. Accessed October 31, 2011.
32. Diagnostic Test Accuracy Working Group. Handbook for diagnostic test accuracy reviews. Available from: http://srdta.cochrane.org/handbook-dta- reviews. 2011, Accessed October 31, 2011.
33. Clad A, Reuschenbach M, Weinschenk J, et al. Performance of the APTIMA high-risk HPV mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology. J Clin Microbiol 2011; 49: 1071-6.
34. Monsonego J, Hudgens MG, Zerat L, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid based cytology in primary cervical cancer screening (The FASE study). Int J Cancer 2011; 129: 691-701.
35. Ratnam S, Coutlee F, Fontaine D, et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol 2011; 49: 557-64.
36. Szarewski A, Ambroisine L, Cadman L, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008; 17: 3033-43.
37. Wu R, Belinson SE, Du H, et al. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I. Int J Gynecol Cancer 2010; 20: 1411-14.
38. Cuschieri K, Kitchener H, Horne AW, et al. Clinical performance of a broad-spectrum RNA assay in a high-prevalence disease setting. In 26th international Papillomavirus Conference and Clinical and Public Health Workshops, Montreal, 2010.
39. Gen-Probe. APTIMA HPV Assay. Available from: http://www.accessdata.fda. gov/cdrh-docs/pdf10/P100042c.pdf. 2011:-502170 rev. A. 502170 rev. A. Accessed November 30, 2011.
40. Getman D, Aiyer A, Dockter J, et al. Efficiency of the APTIMA HPV assay for detection of HPV RNA and DNA targets. J Clin Virol 2009; 45 (Suppl. 1): S49-S54.
41. Castle PE, Dockter J, Giachetti C, et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 2007; 13: 2599-605.
42. Cuzick J, Ambroisine L, Cadman L, et al. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. J Med Virol 2010; 82: 1186-91.
43. Reuschenbach M, Clad A, Knebel Doeberitz C, et al. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol Oncol 2010; 119: 98-105.
44. European Commission. European guidelines for quality assurance in cervical cancer screening. Luxembourg: Office for Official Publications of the European Communities, 2008. 291.
45. Arbyn M, Roelens J, Martin-Hirsch P, et al. Use of HC2 to triage women with borderline and mild dyskaryosis in the UK. Br J Cancer 2011; 105: 877-80.
46. Waldstrom M, Ornskov D,. Clinical performance of a human papillomavirus messenger RNA test (APTIMA HPV assay) on residual material from archived 3-year-old preservcyt samples with low-grade squamous intraepithelial lesion. Arch Pathol Lab Med 2011; 135: 1052-6.
47. Ovestad IT, Vennestrom U, Andersen L, et al. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol 2011; 123: 278-83.
48. Castle PE, Solomon D, Wheeler CM, et al. Human papillomavirus genotype specificity of Hybrid Capture 2. J Clin Microbiol 2008; 46: 2595-604.
49. Atkins D, Best D, Briss PA, et al, GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
50. Schunemann HJ, Oxman AD, Brozek J, et al. GRADE: grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336: 1106-10.